All News

infusion.biologic.jpg

Best of 2020: Infusions in the Time of Coronavirus

d Eric Ruderman, MD

After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week. One of the few good things to come out of this crisis is that we may learn that in-person visits are not as critical as we thought, which may in turn help our specialty’s access issues. The only thing we can’t do remotely, however, are infusions.

Read Article
Lifestyle, Clinical Risk Factors for RA-ILD: Dr. Sheila Reyes #acr20 https://t.co/7LQ7RCtiuj https://t.co/Sjn5PN9FT6

Links:

Dr. John Cush RheumNow ( View Tweet)
#Bestof2020 Infusions in the Time of Coronavirus https://t.co/XR0Rgcdyo0 https://t.co/X70bexfIxL

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Lessons from the clinic Stopping DMARDs & Biologics for Surgery Featuring Dr. Jack Cush https://t.co/W2OseFl1lp https://t.co/M6drktNiBK

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Eric Dein ( @ejdein1) discusses abstracts #0049 (accessing patient portals) and #0045 (assessing rashes in patients of color in lupus) #acr20 https://t.co/J31EoCnA7i

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Janet Pope ( @Janetbirdope) interviews Arthritis & Rheumatology Editor Dr. Daniel Solomon about his role as editor, COVID-19 related submissions, and overall journal submissions #ACR20 https://t.co/ph2gVCVe0f

Links:

Dr. John Cush RheumNow ( View Tweet)

Race/ethnicity Associated with Poor Outcomes in Rheum Patients with COVID-19 : Dr. Dey ( @DrMiniDey) #acr20 https://t.co/ecenB2i5At https://t.co/q8QJ5CxqBF

Links:

Dr. John Cush RheumNow ( View Tweet)
For 2021 -- Innovate, Create, Share as you build a community -Seth Godin https://t.co/NYvf87ASaf

Links:

Dr. John Cush RheumNow ( View Tweet)

Download our document on maintaining a healthy immune system https://t.co/wiWzZldnik https://t.co/fO5yvnrphB

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID Vaccine Q & A - Dr Kevin Winthrop talks on the use and caveats to COVID-19 vaccination in patients with rheumatic disease and taking biologic and DMARD therapies. https://t.co/EJL6hVLnrp https://t.co/xkCRRHtkV9

Links:

Dr. John Cush RheumNow ( View Tweet)
#Bestof2020 Some Good Things During the Time of COVID-19 https://t.co/s3SsxFNAyF https://t.co/b9YjxDdQTx

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets Cohort study from NYC shows that patients w/COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressive https://t.co/9mnb05Xqfa

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets Racial/ethnic minorities with rheum Dz(RD) & COVID had increased odds of hospitalization & vent support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital https://t.co/Aa5UHwvXTA https://t.co/cFk8z8p985

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/0kiJpq46pE https://t.co/iQHGE47Hfd

Links:

Dr. John Cush RheumNow ( View Tweet)
#Bestof2020 The COVID-19 Global Rheumatology Registry by Dr. Kathryn Dao ( @KDAO2011) https://t.co/fmAbFYtLQ8 https://t.co/EQE0Cp14zZ

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ATSCPAssembly : Dr. Dinesh Khanna ( @sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD.

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @drpnash : Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/bSkedaRwfv #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs

Links:

Dr. John Cush RheumNow ( View Tweet)

The core problem of COI amongst docs is that the profession does not really care. Disclosure is not the solution. Divestment and recusal are, but no one inside wants to do that. This was a case of failure to disclose (on a large scale) and the punishment was a promotion https://t.co/Q384TNnPy2

Links:

Vinay Prasad VPrasadMDMPH ( View Tweet)

#BestACR20Tweet RT @KDAO2011 : Abstr#0545 TCZ and Tofa may be safe in patients with resolved Hepatitis B infection. MGH study of 20 pts given TCZ or Tofa, followed 4 years; 25% on antivirals, but no cases of transaminitis from HBV or reactivation of HBV seen. #ACR20 @rheumnow

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @KDAO2011 : Abstr#0013 TEASER! Colchicine may improve COVID19 outcomes in hospitalized patients. 50 pts 1:1 colchicine vs. PCB + standard of care: Colchicine group 2X more likely to be d/c from hospital, and less likely to die. Larger studies needed! #ACR20

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×